Avecho Biotechnology (ASX:AVE) Debt-to-Equity : 0.03 (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology Debt-to-Equity?

Avecho Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.08 Mil. Avecho Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.10 Mil. Avecho Biotechnology's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$6.38 Mil. Avecho Biotechnology's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Avecho Biotechnology's Debt-to-Equity or its related term are showing as below:

ASX:AVE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.03 Max: 0.1
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of Avecho Biotechnology was 0.10. The lowest was 0.02. And the median was 0.03.

ASX:AVE's Debt-to-Equity is ranked better than
81.67% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs ASX:AVE: 0.03

Avecho Biotechnology Debt-to-Equity Historical Data

The historical data trend for Avecho Biotechnology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology Debt-to-Equity Chart

Avecho Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.06

0.02

0.10

0.03

Avecho Biotechnology Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.01	0.10	0.10	0.03

Competitive Comparison of Avecho Biotechnology's Debt-to-Equity

For the Biotechnology subindustry, Avecho Biotechnology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avecho Biotechnology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's Debt-to-Equity falls into.

Avecho Biotechnology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Avecho Biotechnology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.077	+	0.098)	/	6.378
	=	0.03

Avecho Biotechnology's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.077	+	0.098)	/	6.378
	=	0.03

Avecho Biotechnology (ASX:AVE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Avecho Biotechnology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Avecho Biotechnology (ASX:AVE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

OEZ:Germany

Address

Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168

Website

https://www.avecho.com.au

Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sale, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology (ASX:AVE) Headlines

No Headlines